Literature DB >> 27641736

Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.

Ling-Ling Peng1,2, Yuan-Qi Zhao3, Zi-Yi Zhou3, Jing Jin1, Min Zhao3, Xin-Meng Chen1, Ling-Yan Chen1, Ye-Feng Cai3, Jia-Li Li1, Min Huang1.   

Abstract

AIM: Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events. Numerous evidence shows that thromboxane A2 receptor (TXA2 receptor, encoded by TBXA2R), lipoprotein-associated phospholipase A2 (Lp-PLA2, encoded by PLA2G7) and platelet endothelial aggregation receptor-1 (PEAR1, encoded by PEAR1) are crucial in regulating platelet activation, and P-glycoprotein (P-gp, encoded by MDR1) influences the absorption of aspirin in the intestine. In this study we examined the correlation between MDR1, TBXA2R, PLA2G7, PEAR1 genetic polymorphisms and platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.
METHODS: A total of 283 ischemic stroke patients receiving 100 mg aspirin for 7 d were genotyped for polymorphisms in MDR1 C3435T, TBXA2R (rs1131882), PLA2G7 (rs1051931, rs7756935), and PEAR1 (rs12566888, rs12041331). The platelet aggregation response was measured using an automatic platelet aggregation analyzer and a commercially available TXB2 ELISA kit.
RESULTS: Thirty-three patients (11.66%) were insensitive to aspirin treatment. MDR1 3435TT genotype carriers, whose arachidonic acid (AA) or adenosine diphosphate (ADP)-induced platelet aggregation was lower than that of CC+CT genotype carriers, were less likely to suffer from aspirin resistance (odds ratio=0.421, 95% CI: 0.233-0.759). The TBXA2R rs1131882 CC genotype, which was found more frequently in the aspirin-insensitive group (81.8% vs 62.4%) than in the sensitive group, was identified as a risk factor for aspirin resistance (odds ratio=2.712, 95% CI: 1.080-6.810) with a higher level of AA-induced platelet aggregation. Due to the combined effects of PLA2G7 rs1051931 and rs7756935, carriers of the AA-CC haplotype had a higher level of ADP-induced platelet aggregation, and were at considerably higher risk of aspirin resistance than noncarriers (odds ratio=8.233, 95% CI: 1.590-42.638).
CONCLUSION: A considerable portion (11.66%) of Chinese ischemic stroke patients are insensitive to aspirin treatment, which may be correlated with the MDR1 C3435T, TBXA2R (rs1131882), and PLA2G7 (rs1051931-rs7756935) polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27641736      PMCID: PMC5099418          DOI: 10.1038/aps.2016.90

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  28 in total

1.  Laboratory detection of 'aspirin resistance': what test should we use (if any)?

Authors:  Marco Cattaneo
Journal:  Eur Heart J       Date:  2007-06-22       Impact factor: 29.983

2.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

Authors:  P A Gum; K Kottke-Marchant; E D Poggio; H Gurm; P A Welsh; L Brooks; S K Sapp; E J Topol
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

Review 3.  Stroke and stroke care in China: huge burden, significant workload, and a national priority.

Authors:  Liping Liu; David Wang; K S Lawrence Wong; Yongjun Wang
Journal:  Stroke       Date:  2011-11-03       Impact factor: 7.914

4.  The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

Authors:  S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

Review 5.  COX-2 and prostaglandins in atherosclerosis.

Authors:  F Cipollone
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Association of aspirin resistance with increased stroke severity and infarct size.

Authors:  Amy S Y Zheng; Leonid Churilov; Ruth E Colley; Christine Goh; Stephen M Davis; Bernard Yan
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

7.  Aspirin resistance in patients with acute ischemic stroke.

Authors:  Serkan Ozben; Beste Ozben; Azra Meryem Tanrikulu; Feriha Ozer; Tomris Ozben
Journal:  J Neurol       Date:  2011-04-21       Impact factor: 4.849

8.  Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients.

Authors:  Pilar Delgado; Pilar Chacón; Anna Penalba; Dolors Pelegri; Teresa García-Berrocoso; Dolors Giralt; Estevo Santamarina; Marc Ribó; Olga Maisterra; José Alvarez-Sabín; Anna Rosell; Joan Montaner
Journal:  Cerebrovasc Dis       Date:  2011-12-14       Impact factor: 2.762

9.  Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.

Authors:  Joshua P Lewis; Kathleen Ryan; Jeffrey R O'Connell; Richard B Horenstein; Coleen M Damcott; Quince Gibson; Toni I Pollin; Braxton D Mitchell; Amber L Beitelshees; Ruth Pakzy; Keith Tanner; Afshin Parsa; Udaya S Tantry; Kevin P Bliden; Wendy S Post; Nauder Faraday; William Herzog; Yan Gong; Carl J Pepine; Julie A Johnson; Paul A Gurbel; Alan R Shuldiner
Journal:  Circ Cardiovasc Genet       Date:  2013-02-07

Review 10.  Pharmacogenomics of platelet responsiveness to aspirin.

Authors:  Nauder Faraday; Diane M Becker; Lewis C Becker
Journal:  Pharmacogenomics       Date:  2007-10       Impact factor: 2.533

View more
  8 in total

Review 1.  PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases.

Authors:  Narges Ansari; Sahar Najafi; Saied Shahrabi; Najmaldin Saki
Journal:  J Thromb Thrombolysis       Date:  2021-01       Impact factor: 2.300

Review 2.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

3.  Targeted deep sequencing of the PEAR1 locus for platelet aggregation in European and African American families.

Authors:  Ali R Keramati; Lisa R Yanek; Kruthika Iyer; Margaret A Taub; Ingo Ruczinski; Diane M Becker; Lewis C Becker; Nauder Faraday; Rasika A Mathias
Journal:  Platelets       Date:  2018-03-19       Impact factor: 3.862

4.  Effect of 106PEAR1 and 168PTGS1 genetic polymorphisms on recurrent ischemic stroke in Chinese patient.

Authors:  Jiali Zhao; Fudi Chen; Lin Lu; Hui Tang; Ruirui Yang; Yongxiang Wang; Yifeng Du
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 5.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

6.  Cell-Specific PEAR1 Methylation Studies Reveal a Locus that Coordinates Expression of Multiple Genes.

Authors:  Benedetta Izzi; Fabrizia Noro; Katrien Cludts; Kathleen Freson; Marc F Hoylaerts
Journal:  Int J Mol Sci       Date:  2018-04-03       Impact factor: 5.923

7.  Variants of PEAR1 Are Associated With Outcome in Patients With ACS and Stable CAD Undergoing PCI.

Authors:  Fabian Stimpfle; Maike Bauer; Dominik Rath; Elke Schaeffeler; Matthias Schwab; Meinrad Gawaz; Stefan Winter; Tobias Geisler
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

8.  Variation of PEAR1 DNA methylation influences platelet and leukocyte function.

Authors:  Benedetta Izzi; Francesco Gianfagna; Wen-Yi Yang; Katrien Cludts; Amalia De Curtis; Peter Verhamme; Augusto Di Castelnuovo; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Jan A Staessen; Marc F Hoylaerts; Licia Iacoviello
Journal:  Clin Epigenetics       Date:  2019-10-29       Impact factor: 6.551

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.